Background: Pyoderma gangrenosum (PG)
with impact on quality of life. Discussion: An immune-modulatory monotherapy with adalimumab is a viable treatment option for recalcitrant PG. Thanks to the easy administration, rare side effects, and good healing action it is a convincing therapeutic strategy.
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The pathergy phenomenon is often positive [1] . Extracutaneous manifestation involving mucosal structures of the upper airways, the eyes, or the genital area have been observed [2] . PG is often associated with systemic disorders such as Crohn's disease, colitis ulcerosa, rheumatoid arthritis or rheumatoid arthritislike processes, and paraproteinemia. After healing, PG lesions leave typical scars with a knitted look.
The first therapeutic step is the use of local and systemic corticosteroids. In extensive cases, steroid-sparing agents such as ciclosporine, azathioprine, dapsone, methotrexate, mycophenolate mofetil, tacrolimus, intravenously applied immunoglobulines, colchicine, or 5-aminosalicylate, can be used with unpredictable and often poor outcomes [3] .
CASE REPORT
A 42-year-old woman with recalcitrant PG was first presented in the dermatology department After the first pulse the ulcerations in the hypogastric area resolved, but after the second cycle of this therapy the patient noticed nausea, dizziness, and shortness of breath. Therefore, this treatment was discontinued.
After excluding any contraindications the authors implemented a subcutaneouslyadministered therapy with adalimumab starting with 80 mg in week 0 and 40 mg in week 1, followed by 40 mg every second week in October 2010. The patient gave written informed consent to the off-label use of adalimumab. The ulceration measured 15 9 30 cm when starting this treatment (Fig. 1a) . Under this therapy, the ulceration got steadily smaller and healed nearly completely within 64 weeks (Fig. 1b) . Systemic therapy with oxycodone could be lowered after 41 weeks of treatment and finally stopped in January 2012. However, treatment with adalimumab was resumed, with the intent of consolidation and treatment success, but application intervals were extended to 4-week intervals. Therapy with adalimumab was welltolerated without any side effects and led to an increased quality of life, measured with the Dermatology Life Quality Index (DLQI) (Fig. 2) .
To the author's knowledge this is the first case report that shows an objective improvement in quality of life by using the DLQI score.
DISCUSSION
New therapeutic strategies take into account that patients with inflammatory bowel disease, which is frequently associated with PG, present increased levels of tumor necrosis factor-a (TNF-a). Furthermore, PG itself seems to be associated with high serum levels of TNF-a, resulting from an abnormal T-cell response in PG patients. Hence, several authors presumed that inhibition of TNF-a could effectively treat PG [4] [5] [6] [7] . In recent years, a growing rate of case reports about successful treatment of PG by the use of TNF-a-inhibitors such as etanercept, infliximab, and adalimumab have been published. Furthermore, Hubbard et al. [6] state that the rate of antibody production against adalimumab, a fully human product, is only 12% compared to 75% in the case of infliximab, a chimeric monoclonal anti-TNF-a antibody. In 2007, Pomerantz et al. [7] 
CONCLUSION
Due to several reports of successful treatment and due to the author's observations, adalimumab is a viable treatment option for recalcitrant PG.
Owing to the easy administration, rare side effects and good healing action it is a convincing therapeutic strategy.
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